A multicenter, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of SA237 as monotherapy in patients with neuropyelitis optica (NMO)

To evaluate the effectiveness and safety of under the skin injection of SA237 as monotherapy in patients with NMO.

Primary Sponsor:
Chugai Pharmaceuticals

Prinicipal Investigator:
Ted Rothstein, MD

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):